This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tolman, J. A.
Right arrow Articles by Williams, R. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tolman, J. A.
Right arrow Articles by Williams, R. O., III

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2009, p. 2613-2615, Vol. 53, No. 6
0066-4804/09/$08.00+0     doi:10.1128/AAC.01657-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Inhaled Voriconazole for Prevention of Invasive Pulmonary Aspergillosis{triangledown}

Justin A. Tolman,1 Nathan P. Wiederhold,1,2* Jason T. McConville,1 Laura K. Najvar,3,4 Rosie Bocanegra,3,4 Jay I. Peters,4,5 Jacqueline J. Coalson,6 John R. Graybill,3 Thomas F. Patterson,3,4 and Robert O. Williams III1*

The University of Texas at Austin College of Pharmacy, Austin, Texas,1 The University of Texas Health Science Center at San Antonio, Pharmacotherapy Education and Research Center, San Antonio, Texas,2 The University of Texas Health Science Center at San Antonio, Department of Medicine, Division of Infectious Diseases, San Antonio, Texas,3 South Texas Veterans Health Care System, San Antonio, Texas,4 The University of Texas Health Science Center at San Antonio, Department of Medicine, Division of Pulmonary Diseases/Critical Care Medicine, San Antonio, Texas,5 The University of Texas Health Science Center at San Antonio, Graduate School of Biomedical Sciences, Department of Pathology, San Antonio, Texas6

Received 17 December 2008/ Returned for modification 19 January 2009/ Accepted 6 March 2009

Targeted airway delivery of antifungals as prophylaxis against invasive aspergillosis may lead to high lung drug concentrations while avoiding toxicities associated with systemically administered agents. We evaluated the effectiveness of aerosolizing the intravenous formulation of voriconazole as prophylaxis against invasive pulmonary aspergillosis caused by Aspergillus fumigatus in an established murine model. Inhaled voriconazole significantly improved survival and limited the extent of invasive disease, as assessed by histopathology, compared to control and amphotericin B treatments.

* Corresponding author. Mailing address for Nathan P. Wiederhold: UTHSCSA, PERC MSC 6220, 7703 Floyd Curl Drive, San Antonio, TX 78229. Phone: (210) 567-8340. Fax: (210) 567-8328. E-mail: wiederholdn{at}uthscsa.edu. Mailing address for Robert O. "Bill" Williams III: The University of Texas at Austin, 1 University Station, A1920, Austin, TX 78712. Phone: (512) 471-4681. Fax: (512) 471-7474. E-mail: williro{at}mail.utexas.edu

{triangledown} Published ahead of print on 16 March 2009.

Antimicrobial Agents and Chemotherapy, June 2009, p. 2613-2615, Vol. 53, No. 6
0066-4804/09/$08.00+0     doi:10.1128/AAC.01657-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»